European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Dec 2015
Randomized Controlled TrialDexmedetomidine pharmacokinetics in the obese.
This study aims to characterize the influence of body weight and composition on the pharmacokinetics of dexmedetomidine. ⋯ The use of theory-based allometry with predictions of fat free mass has been able to separate the influences of weight and body composition and indicates that size-normalized clearance of dexmedetomidine is impaired in patients who are obese.
-
Eur. J. Clin. Pharmacol. · Dec 2015
Clinical Trial Controlled Clinical TrialThe effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
To investigate the potential effects of strong CYP3A inhibitor ketoconazole and strong CYP3A inducer rifampin on the pharmacokinetics of crizotinib in human. ⋯ These findings suggest that CYP3A plays an important role in the metabolism of both crizotinib and PF-06260182, with the extent of this role being greater for PF-06260182. There were no serious adverse events or deaths and no dose reductions or temporary or permanent discontinuations due to drug-related adverse events in either study.